Caraway Therapeutics has been awarded a research grant from The Michael J. Fox Foundation to further investigate a lysosomal ion channel that could be key in developing a new class of therapeutics for Parkinson’s disease. “Receiving this grant from The Michael J. Fox Foundation is extremely validating for…
Dimethyltryptamine or DMT, one of the main natural components of traditional Amazonian ayahuasca tea, promotes the formation of new nerve cells (neurogenesis), a recent study suggests. Researchers say the compound might have “great therapeutic potential” for treating a range of neurological disorders, including neurodegenerative diseases such as Alzheimer’s…
A rare neurodegenerative disorder called neuronal intranuclear inclusion body disease (NIID) may share a similar genetic mutation with Parkinson’s disease (PD), a study suggests. Patients who present with typical Parkinson’s disease may carry this mutation, respond to parkinsonian medications and not develop clinical features of NIID. The study, “Association…
A Phase 1 clinical trial evaluating umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment of bradykinesia — slowness or difficulty with movement — in people with Parkinson’s disease is expected to soon open in the U.S. Recruitment is expected to go well, and dosing of a first patient…
The Brain Mind Institute has joined with Idorsia Pharmaceuticals in a three-year effort to discover and develop new therapies for Parkinson’s disease and other neurodegenerative disorders. “This collaboration combines some of the best skills and know-how from academia and industry with the common objective of finding new small molecules…
Anavex 2-73 (blarcamesine), a potential oral therapy to slow cognitive decline due to Alzheimer’s and other neurological disorders, was found to be safe and to lead to clinically meaningful, dose-dependent improvements in cognition in people with Parkinson’s disease dementia (PDD) treated in a Phase 2 trial. Anavex…
The interplay between different genetic and environmental factors, from a family history of disease to smoking habits, contributes to Parkinson’s risk and can help in designing tests that better allow for its early detection, a study suggests. The study, “Parkinson’s disease determinants, prediction and gene–environment interactions in the UK…
An innovative computational approach for identifying new alpha-synuclein tracer molecules could be used to track the progression of Parkinson’s disease, according to a recent study. The study, “Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughput in silico…
A new compound called CLR01, which works like a “molecular tweezer” to clear toxic protein clumps that accumulate in brain cells, could become a promising therapy to slow Parkinson’s disease progression, a study suggests. The study, “CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s…
Previous falls, hallucinations, and cognitive problems are among the factors that predict a risk of recurrent falls in elderly people with parkinsonian gait, a study suggests. The study, “Parkinsonian gait in elderly people: Significance of the threshold value of two and more falls per year,” was published in the…
Get regular updates to your inbox.